Reversal of Ventricular Remodeling With Toprol-XL

• Status: Completed
• Trial end date: 2003-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Metoprolol

Criteria

Inclusion Criteria:

• Diagnosis of stable asymptomatic heart failure.

• Documented ejection fraction less than 0.40.

• Must be able to comply with all study procedures.

Exclusion Criteria:

• Taken B-blocker therapy for longer than 1 week within 6 months prior to randomization.

• Have heart problems that would not allow B-blocker therapy.

• Receiving B-blockers therapy for any medical reason including topical B-blockers that might cause systemic absorption (e.g., glaucoma).

• Undergone certain heart surgeries, such as, prior heart transplant or cardiomyoplasty.

• Have certain heart diseases.

• Pregnant or breast feeding.

• Unlikely to survive.